^
Association details:
| Biomarker: | ETV6-NTRK3 fusion |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The incidence of NTRK fusion in Chinese head and neck cancer and response to crizotinib treatment.
Published date:
05/28/2020
Excerpt:
A parotid cancer patient with lung metastasis harboring ETV6-NTRK3 fusion underwent Crizotinib treatment after disease progressed with chemotherapy...In brief, the patient reached a progression-free survival (PFS) of 2 years....ETV6-NTRK3 fusion patient reached long-term response (2 years) with Crizotinib, indicating alternative therapy insights to Head and Neck Cancer patients.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2020.38.15_suppl.e18532
